Company intelligence / Profile preview

Bryan & Company

Ownership: Private
Development stage: Other

Overview

Bryan Therapeutics focuses on developing drugs that restore or generate nitric oxide in the human body. Their lead programs include a topical wound care product and an orally disintegrating lozenge targeting cardiovascular diseases and COVID‑19. The company leverages Dr. Nathan S. Bryan’s research and patents around nitric oxide biology. Some products are moving toward clinical trials or regulatory fast track status.[1]

Therapeutic areas: DermatologyCardiovascularInfectious Diseases
Modalities: Small moleculeTopical therapyBiologic
Industry: Biotech

Drug pipeline

1 asset

talc

Approved

Beyond the preview

Go deeper on Bryan & Company.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bryan & Company.

Explore the full profile